<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157140</url>
  </required_header>
  <id_info>
    <org_study_id>320.6750.19089-49</org_study_id>
    <nct_id>NCT04157140</nct_id>
  </id_info>
  <brief_title>Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC</brief_title>
  <official_title>Anlotinib Hydrochloride In Combination With Radiofrequency Ablation And Transcatheter Arterial Chemoembolization in Patients With Middle-advanced Hepatocellular Carcinoma, Open, Single Arm, Exploratory Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinglong Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Ditan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib
      hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial
      chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time To Progression(TTP)</measure>
    <time_frame>each 42 days up to progressive disease (PD) (up to 24 months)</time_frame>
    <description>Time To Progression is defined as the time from first day of TACE treatment until the first date of either objective disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Objective response rate is defined as the percentage of subjects whose best response was complete response (CR) or partial response (PR) according to the Modified Response Evaluation Criteria in Solid Tumors Version (mRECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Disease control rate is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time Frame: each 42 days up to intolerance the PD or death (up to 24 months)</time_frame>
    <description>Duration of Response is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the mRECIST or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Until 30 day safety follow-up visit</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib+ TACE+ RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib+ TACE+ RFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.</description>
    <arm_group_label>Anlotinib+ TACE+ RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TACE+RFA</intervention_name>
    <description>TACE first, followed by RFA within day7（+/-3days）</description>
    <arm_group_label>Anlotinib+ TACE+ RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients participate in the study voluntarily and sign informed consent with good
             compliance.

          -  Histological or cytological confirmation of unrespectable middle-advanced
             hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage Category C or B , liver
             function child-Pugh class A or B (≤7 points).

          -  At least one measurable lesion, with diameter ≥ 10mm measured by spiral MRI/CT scan
             per mRECIST; have not received local therapies including but not limited to TACE, RFA,
             radiotherapy and cryosurgery.-Eastern Cooperative Oncology Group Performance Status 0
             or 1.

          -  Life expectancy of at least 3 months.

          -  Main organs function is normal. (normal main organs function as defined below:
             Hemoglobin (Hb) ≥ 90 g/L, Neutrophils (ANC) ≥ 1.5×109/L, leucocyte (WBC) ≥ 3.0×109/L,
             Platelet count (PLT) ≥ 70×109/L, Total bilirubin (TBIL) ≤ 1.5 × normal upper limit
             (ULN), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 ×ULN,
             Serum creatinine (Cr) ≤ 1.5× ULN or Creatinine Clearance rate(CCr) ≥60ml/min,Doppler
             ultrasound evaluation: left ventricular ejection fraction (LVEF) &gt; 50%)

          -  The woman patients of childbearing age who must agree to take contraceptive methods
             (e.g. intrauterine device, contraceptive pill or condom) during the research and
             within another 3 months after it; who are not in the lactation period and examined as
             negative in blood serum test or urine pregnancy test within 7 days before the
             research; The man patients who must agree to take contraceptive methods during the
             research and within another 8 weeks after it.

          -  Patients have disease that is not amenable to potentially curative transplantation or
             ablation

          -  Patients who have characterization for targeted therapy treatment, but under poor
             economic conditions and cannot afford angiogenesis inhibitors recommended by current
             guidelines, including Lenvatinib, sorafenib, Cabozantinib, Ramolumab, regorafenib,
             etc.

        Exclusion Criteria:

          -  History of other malignancy within 5 years or for now (except for non-melanoma skin
             cancer, cervix in situ carcinoma, superficial Bladder neoplasms).

          -  Subject has obstacle in the function of major organs such as heart, lung, liver and
             kidney

          -  Patients who plan liver transplantation.

          -  Patients who had previously received treatment with target inhibitors or other
             immunotherapy against or chemotherapy

          -  Patients who had previously received treatment with TACE or or other local therapy or
             radiotherapy or Chinese medicine treatment within 4 weeks.

          -  Liver function status Child-Pugh Class C, with malignant ascites.

          -  Participated in other anti-tumor clinical trials within 4 weeks.

          -  Symptoms that affect oral medication and cannot be controlled through proper treatment
             (such as inability to swallow, chronic diarrhoea and intestinal obstruction, etc.).

          -  Any of the following coagulation functions are abnormal, including: Prothrombin time
             (PT)＞ULN+4s, Activated partial thromboplastin time (APTT) ＞1.5ULN s, nternational
             normalized ratio (INR)＞1.5

          -  Patients who underwent major surgery within 4 weeks.

          -  Patients who have got non remissive toxic reactions derived from any treatment, which
             is over level 1 in CTC AE (4.0).

          -  Patients with any severe and/or unable to control diseases，including： Patients with
             unsatisfactory blood pressure control using antihypertensive drugs (systolic blood
             pressure ≥150 mmHg or diastolic blood pressure ≥100) mmHg); Patients with Grade 1 or
             higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including
             QTc≥480ms) and patients with Grade 2 or higher congestive heart failure (NYHA
             Classification); Patients with active or unable to control serious infections, which
             is over level 2 in CTC AE (4.0); Patients with poorly controlled diabetes (fasting
             blood glucose(FBG)＞10mmol/L); Patients with kidney failure who require hemodialysis or
             peritoneal dialysis; Patients with a history of immunodeficiency, including a positive
             HIV test or other acquired, congenital immunodeficiency disease, or a history of organ
             transplantation; Urine routine indicates that urine protein ≥ ++, and confirmed
             24-hour urine protein quantitation &gt; 1.0 g.

          -  Patients whose tumors had invaded important blood vessels by imaging or who, as
             determined by the researchers, were likely to invade important blood vessels during
             follow-up trial, resulting in fatal bleeding.

          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such
             as cerebrovascular accident (including transient ischemic attack), deep vein
             thrombosis and pulmonary embolism.

          -  Regardless of the severity, patients with any physical signs or history of bleeding,
             patients with bleeding or bleeding events greater than or equal to CTCAE 3 within four
             weeks prior to the first administration, or patients with unhealed wounds, fractures,
             ulcers.

          -  Patients with Brain metastases.

          -  Patients with cancer thrombus involving whole the main portal vein.

          -  Female patients who are pregnant or breastfeeding.

          -  Patients with drug abuse history and unable to get rid of or patients with mental
             disorders.

          -  Patients with concomitant diseases which could seriously endanger their own safety or
             could affect completion of the study according to investigators' judgment.

          -  History of gastrointestinal bleeding due to severe gastroesophageal varices within 4
             weeks.

          -  Severe active or uncontrolled infections.

          -  Patients who had serious adverse effect to Anlotinib.

          -  Patients who had serious adverse effect to iodinated contrast agent.

          -  Liver cirrhosis, hepatic decompensation, active hepatitis or chronic hepatitis which
             requires anti-viral treatment. Hepatitis C virus (HCV) antibody test shows positive
             and titer test shows amount of HCV exceeds upper limit of normal (ULN) after treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>XiaoYan Ding, M.D</last_name>
    <phone>13811560276</phone>
    <phone_ext>+86</phone_ext>
    <email>dingxiaoyan198111@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Ding, M.D.</last_name>
      <phone>13811560276</phone>
      <phone_ext>+86</phone_ext>
      <email>dingxiaoyan198111@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaiming Lu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 30, 2019</last_update_submitted>
  <last_update_submitted_qc>November 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Ditan Hospital</investigator_affiliation>
    <investigator_full_name>Jinglong Chen</investigator_full_name>
    <investigator_title>Chief of Oncology</investigator_title>
  </responsible_party>
  <keyword>anlotinib</keyword>
  <keyword>HCC</keyword>
  <keyword>TACE</keyword>
  <keyword>RFA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

